BioMarin Pharmaceutical Inc. is a global rare disease biotechnology company founded in 1997. The company focuses on genetic discovery to develop treatments for rare genetic conditions, with nine approved therapies currently available. Its work spans technical domains including genetics, molecular biology, enzyme replacement therapies, and gene therapy.
The company operates in more than 70 countries worldwide and employs approximately 3,000 people. BioMarin describes its culture as rooted in collaboration and purpose, with teams empowered to pursue genetic discoveries and solve problems that have not been solved before.
